Author: Shi, Lei; Wang, Lifeng; Xu, Ruonan; Zhang, Chao; Xie, Yunbo; Liu, Kai; Li, Tiantian; Hu, Wei; Zhen, Cheng; Wang, Fu-Sheng
Title: Mesenchymal stem cell therapy for severe COVID-19 Cord-id: x2ub2pr6 Document date: 2021_9_8
ID: x2ub2pr6
Snippet: The coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has placed a global public burden on health authorities. Although the virological characteristics and pathogenesis of COVID-19 has been largely clarified, there is currently no specific therapeutic measure. In severe cases, acute SARS-CoV-2 infection leads to immune disorders and damage to both the adaptive and innate immune responses. Having roles in immune regulation and regeneratio
Document: The coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has placed a global public burden on health authorities. Although the virological characteristics and pathogenesis of COVID-19 has been largely clarified, there is currently no specific therapeutic measure. In severe cases, acute SARS-CoV-2 infection leads to immune disorders and damage to both the adaptive and innate immune responses. Having roles in immune regulation and regeneration, mesenchymal stem cells (MSCs) serving as a therapeutic option may regulate the over-activated inflammatory response and promote recovery of lung damage. Since the outbreak of the COVID-19 pandemic, a series of MSC-therapy clinical trials has been conducted. The findings indicate that MSC treatment not only significantly reduces lung damage, but also improves patient recovery with safety and good immune tolerance. Herein, we summarize the recent progress in MSC therapy for COVID-19 and highlight the challenges in the field.
Search related documents:
Co phrase search for related documents- activate inflammatory response and acute respiratory syndrome: 1, 2, 3
- activate inflammatory response and adaptive immunity: 1
- activate inflammatory response and adaptive innate: 1, 2, 3, 4
- activate inflammatory response suppress and acute ards respiratory distress syndrome: 1
- activate inflammatory response suppress and acute respiratory syndrome: 1
- acute ards respiratory distress syndrome and adaptive immunity: 1, 2, 3, 4, 5, 6, 7
- acute ards respiratory distress syndrome and adaptive innate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
- acute ards respiratory distress syndrome and adaptive innate immune response: 1, 2, 3, 4, 5, 6, 7
- acute ards respiratory distress syndrome and adipose tissue: 1, 2, 3, 4
- acute ards respiratory distress syndrome and administration regimen: 1
- acute ards respiratory distress syndrome and administration route: 1, 2, 3, 4, 5, 6, 7
- acute ards respiratory distress syndrome and long term follow: 1, 2, 3, 4, 5
- acute inflammatory response and adaptive innate: 1, 2, 3, 4, 5, 6
- acute inflammatory response and adaptive innate immune response: 1, 2
- acute inflammatory response and administration route: 1, 2
- acute inflammatory response and long term follow: 1
- acute respiratory syndrome and administration regimen: 1, 2, 3, 4
- acute respiratory syndrome and administration route: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory syndrome and long term follow: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
Co phrase search for related documents, hyperlinks ordered by date